Evaluation of Dasatinib and Ponatinib for the Control of CD123 CAR T Cell Functionalities

By
Jamie Kang
-
0
45
Investigators evaluated the capacity of two tyrosine kinase inhibitors, dasatinib and ponatinib, to reversibly inhibit CAR T cell functions.
[Molecular Therapy Oncology]
AbstractGraphical Abstract